JDJiajia Duan

Jiajia Duan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiajia Duan has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Bingbing Li

    Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center Institute of Neuroscience and Third Affiliated Hospital of Zhengzhou University Zhengzhou China

    1 shared publication
  • Bingbing Li

    The Third Affiliated Hospital and Institute of Neuroscience of Zhengzhou University, Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, Zhengzhou, Henan, China

    1 shared publication
  • Biping Deng

    Cytology Laboratory, Beijing GoBroad Boren Hospital, Beijing, China

    1 shared publication
  • Changlian Zhu

    Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center Institute of Neuroscience and Third Affiliated Hospital of Zhengzhou University Zhengzhou China

    1 shared publication
  • Changlian Zhu

    Henan Key Laboratory of Child Brain Injury and Henan Pediatric Clinical Research Center, Institute of Neuroscience, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    1 shared publication
  • Chaoya Zhu

    Department of Pathology Third Affiliated Hospital of Zhengzhou University Zhengzhou China

    1 shared publication

Latest Publications

  • Open Access

    Epidemiological and clinical characteristics associated with enterovirus D68 respiratory diseases in Asian children: a systematic review and meta-analysis

    by Xiaojing Lu, Bingbing Li, Shufang Li, Lihong Wang, Guangen Guo, Yanli Zhang, Jiajia Duan, Changlian Zhu


  • Top Cited Papers

    Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial

    by Jing Pan, Yue Tan, Lingling Shan, Samuel Seery, Biping Deng, Zhuojun Ling, Jinlong Xu, Jiajia Duan, Zelin Wang, Kai Wang, et al.

    Refractory or relapsed T cell acute lymphoblastic leukemia (r/r T-ALL) patients have poor prognoses, due to the lack of effective salvage therapies. Recently, CD7-targeting chimeric antigen receptor (CAR)-T therapies show efficacy in patients with r/r T-ALL, but relapse with CD7 loss is common. This study evaluates a CD5-gene-edited CAR-T cell therapy targeting CD5 in 19 r/r T-ALL patients, most of whom had previously failed CD7 CAR-T interventions. CAR-T products were derived from previous transplant donors (Cohort A) or newly matched donors (Cohort B). Primary endpoints were dose-limiting toxicity at 21 days and adverse events within 30 days. Secondary endpoints were responses, pharmacokinetics and severe adverse events after 30 days. A total of 16 received infusions, 10 at target dose of 1 × 106 kg−1. All encountered grade 3–4 cytopenias and one had a grade 3 infection within 30 days. All patients (100%) achieved complete remission or complete remission with incomplete blood count recovery by day 30. At a median follow-up of 14.3 months, four received transplantation; three were in remission and one died of infection. Of 12 untransplanted patients, 2 were in remission, 3 relapsed, 5 died of infection and 2 of thrombotic microangiopathy. CAR-T cells persisted and cleared CD5+ T cells. CD5− T cells, mostly CD5-gene-edited, increased but remained below normal levels. These results suggest this CD5-specific CAR-T intervention has a high remission rate for T-ALL patients. Evidence also suggests the risk of late-onset severe infection may be mitigated with consolidative transplantation. This study provides insights that could help to optimize this promising intervention. ClinicalTrials.gov registration: NCT05032599.


  • Open Access

    Histological chorioamnionitis and pathological stages on very preterm infant outcomes

    by Jiajia Duan, Falin Xu, Chaoya Zhu, Ju Wang, Xiaoli Zhang, Yiran Xu, Bingbing Li, Xirui Peng, Jinjin Zhu, Xiaoyang Wang, et al.

    Aims: Histological chorioamnionitis (HCA) is a condition linked to preterm birth and neonatal infection and its relationship with various pathological stages in extremely preterm neonates, and with their associated short‐ and long‐term consequences, remains a subject of research. This study investigated the connection between different pathological stages of HCA and both short‐term complications and long‐term outcomes in preterm infants born at or before 32 weeks of gestational age.Methods: Preterm infants born at ≤ 32 weeks of gestation who underwent placental pathology evaluation and were followed‐up at 18–24 months of corrected age were included. Neonates were classified based on their exposure to HCA and were further subdivided into different groups according to maternal inflammatory responses (MIR) and fetal inflammatory responses (FIR) stages. We compared short‐term complications during their hospital stay between the HCA‐exposed and ‐unexposed groups and examined the influence of HCA stages on long‐term outcomes.Results: The HCA group exhibited distinct characteristics such as higher rates of premature rupture of membranes > 18 h, reduced amniotic fluid, early‐onset sepsis, bronchopulmonary dysplasia and intraventricular haemorrhage (IVH) grades III–IV (P < 0.05). The moderate–severe HCA group displayed lower gestational age, lower birth weight and higher incidence of IVH (grades III–IV) and preterm sepsis compared with the mild HCA group (P < 0.05). After adjusting for confounders, the MIR stages 2–3 group showed associations with cognitive impairment and cerebral palsy (P < 0.05), and the FIR stages 2–3 group also showed poor long‐term outcomes and cognitive impairment (P < 0.05).Conclusions: Moderate–severe HCA was associated with increased early‐onset sepsis, severe IVH and poor long‐term outcomes, including cognitive impairment and cerebral palsy. Vigilant prevention strategies are warranted for severe HCA cases in order to mitigate poorer clinical outcomes.